CytRx Corporation (NASDAQ: CYTR), is a biopharmaceutical company specializing in oncology. CytRx also maintains a 17% equity interest in RXi Pharmaceuticals (Nasdaq: RXII).
CytRx's drug development pipeline includes programs in Phase 2 clinical development for numerous cancer indications. CytRx recently announced initiation of a Phase 2 clinical trial to evaluate the safety and efficacy of its drug candidate bafetinib in patients with high-risk B-cell chronic lymphocytic leukemia, and plans to initiate three Phase 2 trials with its oncology candidate INNO-206 as a treatment for pancreatic cancer, gastric cancer and soft tissue sarcomas, and two additional Phase 2 proof-of-concept clinical trials with bafetinib in glioblastoma multiforme and advanced prostate cancer. CytRx's pipeline also includes tamibarotene, which is in a registration clinical trial as a treatment for acute promyelocytic leukemia (APL), and CytRx is developing two drug candidates based on the its proprietary molecular chaperone technology which aims to repair or degrade misfolded proteins associated with disease.
Click below to read a recent feature article in the Los Angeles Business Journal about CytRx Corporation and CEO Steven A. Kriegsman Read the article>>>
"Fireside Chat" Webcast Click below to watch a video of CytRx President and CEO Steven A. Kriegsman and Chief Medical Officer Daniel Levitt, M.D., Ph.D. discuss CytRx's corporate strategy and opportunities.
Webcasts 03/16/10 at 11:00 a.m. PT CytRx Corp. at ROTH OC Growth Stock Conference (Replay) More>>>
Investors CytRx is supported by strong financial resources and world-class collaborators to build a pipeline of drug candidates based on molecular chaperone regulation and in the field of oncology.
